The establishment of a novel HB vaccine by using the yeast-derived large-HBs antigen.
Although the current HB vaccine comprising small-HBs antigen (Ag) is potent and safe, attenuated prophylaxis against hepatitis B virus (HBV) with vaccine-escape mutations has been reported. We established an HB vaccine consisting of large-HBsAg that overcomes the drawbacks of the current HB vaccine.
